Literature DB >> 14500353

Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53.

Malisetty V Swamy1, Christopher R Herzog, Chinthalapally V Rao.   

Abstract

Inactivation of the p53 tumor suppressor gene usually involves somatic mutation or binding of viral oncoproteins to the p53 protein. However, several types of malignant and premalignant tissues harbor a genetically wild-type, but transcriptionally inactive, form of p53, often localized in the cytoplasm. Electrophilic prostaglandins (PGs) are known to sequester and inactivate p53 in the cytoplasm, an effect that is likely to occur when cyclooxygenase (COX)-2 levels become elevated during colon carcinogenesis. We determined the localization and expression of p53 in the presence of PGA(1) and celecoxib, a selective COX-2 inhibitor in human colon cell lines HCT-116 (wild-type p53) and HT-29 (mutant p53). In the absence of treatment, p53 protein accumulated preferentially in the nucleus in both cell lines. We observed that the total cellular levels of p53 protein increased with exposure time and concentration of PGA(1). By contrast, p21 protein levels remained unchanged as a function of time and concentration of PGA(1). In the presence of 20 micro M PGA(1), p53 accumulated preferentially in the cytosol. The nuclear:cytosol ratios of p53 were 31 and 2.1 in the controls and in the presence of PGA(1) in HCT-116 cells but were 22 and 4, respectively, in HT-29 cells. Treatment with 50 micro M celecoxib for 24 h did not significantly change p53 expression and localization. However, in the presence of 100 micro M celecoxib, p53 levels increased in the nucleus. The nuclear:cytosol ratios were then 31 (control) and 60 (100 micro M celecoxib) in HCT-116 cells and 22 (control) and 36 (100 micro M celecoxib) in HT-29 cells. These results indicate that electrophilic PGs cause wild-type p53 accumulation in the cytosol where it is inactive. Inhibition of COX-2 by celecoxib appears to alleviate this effect on p53 by reducing electrophilic PG synthesis. Thus, COX-2 inhibition of electrophilic PG formation appears to protect p53 tumor suppressor function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500353

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

Authors:  Chinthalapally V Rao; Jagan Mohan R Patlolla; Li Qian; Yuting Zhang; Misty Brewer; Altaf Mohammed; Dhimant Desai; Shantu Amin; Stan Lightfoot; Levy Kopelovich
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.

Authors:  Pingting Zhou; Yanyan Li; Bo Li; Meichao Zhang; Ci Xu; Furao Liu; Lei Bian; Yuanhua Liu; Yuan Yao; Dong Li
Journal:  Cell Cycle       Date:  2018-06-25       Impact factor: 4.534

3.  Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Authors:  Altaf Mohammed; Naveena B Janakiram; Qian Li; Chang-In Choi; Yuting Zhang; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-01

4.  Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan Marolt; Andrej Cor
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

5.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

Review 6.  Targeting aldose reductase for the treatment of cancer.

Authors:  Ravinder Tammali; Satish K Srivastava; Kota V Ramana
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

7.  Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

8.  Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.

Authors:  Chinthalapally V Rao; Naveena B Janakiram; Altaf Mohammed
Journal:  Curr Colorectal Cancer Rep       Date:  2012-12

9.  Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer.

Authors:  Shuji Ogino; Gregory J Kirkner; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Kaori Shima; Aditi Hazra; Andrew T Chan; Reiko Dehari; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

10.  Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.

Authors:  Khong Bee Kang; Congju Zhu; Sook Kwin Yong; Qiuhan Gao; Meng Cheong Wong
Journal:  Mol Cancer       Date:  2009-08-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.